{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:27:06Z","timestamp":1791149226566,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"13","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heparanase is an enzyme that cleaves heparan sulfate and through this activity promotes tumor growth, angiogenesis, invasion, and metastasis in several tumor types. In human breast cancer patients, heparanase expression is associated with sentinel lymph node metastases. However, the precise role of heparanase in the malignant progression of breast cancer is unknown. To examine this, a variant of MDA-MB-231 cells was transfected with the cDNA for human heparanase (HPSE cells) or with vector alone as a control (NEO cells). Transfection produced a 6-fold increase in heparanase activity in HPSE cells relative to NEO cells. When injected into the mammary fat pads of severe combined immunodeficient mice, the tumors formed by HPSE cells initially grow significantly faster than the tumors formed by NEO cells. The rapid growth is due in part to increased angiogenesis, as microvessel densities are substantially elevated in primary HPSE tumors compared with NEO tumors. Although metastases to bones are not detected, surprisingly vigorous bone resorption is stimulated in animals bearing tumors formed by the HPSE cells. These animals have high serum levels of the C-telopeptide derived from type I collagen as well as significant elevation of the active form of tartrate-resistant acid phosphatase (TRAP)-5b. In contrast, in animals having a high tumor burden of Neo cells, the serum levels of C-telopeptide and TRAP-5b never increase above the levels found before tumor injection. Consistent with these findings, histologic analysis for TRAP-expressing cells reveals extensive osteoclastogenesis in animals harboring HPSE tumors. In vitro osteoclastogenesis assays show that the osteoclastogenic activity of HPSE cell conditioned medium is significantly enhanced beyond that of NEO conditioned medium. This confirms that a soluble factor or factors that stimulate osteoclastogenesis are specifically produced when heparanase expression is elevated. These factors exert a distal effect resulting in resorption of bone and the accompanying enrichment of the bone microenvironment with growth-promoting factors that may nurture the growth of metastatic tumor cells. This novel role for heparanase as a promoter of osteolysis before tumor metastasis suggests that therapies designed to block heparanase function may disrupt the early progression of bone-homing tumors.<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-0749","type":"journal-article","created":{"date-parts":[[2005,9,15]],"date-time":"2005-09-15T21:47:40Z","timestamp":1126820860000},"page":"5778-5784","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Expression of Heparanase by Primary Breast Tumors Promotes Bone Resorption in the Absence of Detectable Bone Metastases"],"prefix":"10.1158","volume":"65","author":[{"given":"Thomas","family":"Kelly","sequence":"first","affiliation":[{"name":"1Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry J.","family":"Suva","sequence":"additional","affiliation":[{"name":"2Center for Orthopedic Research, Departments of Orthopedic Surgery and Physiology and Biophysics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"MacLeod","sequence":"additional","affiliation":[{"name":"1Department of Pathology,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Quan","family":"Miao","sequence":"additional","affiliation":[{"name":"5ImClone Systems, Inc., New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald C.","family":"Walker","sequence":"additional","affiliation":[{"name":"4Radiology and Nuclear Medicine, Arkansas Cancer Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph D.","family":"Sanderson","sequence":"additional","affiliation":[{"name":"1Department of Pathology,"},{"name":"3Department of Neurobiology and Developmental Sciences, and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2005,7,1]]},"reference":[{"key":"2022061620112388000_B1","doi-asserted-by":"crossref","unstructured":"Sanderson RD, Yang Y, Suva LJ, Kelly T. Heparan sulfate proteoglycans and heparanase-partners in osteolytic tumor growth and metastasis. Matrix Biol\u20082004; 236: 341\u201352.","DOI":"10.1016\/j.matbio.2004.08.004"},{"key":"2022061620112388000_B2","doi-asserted-by":"crossref","unstructured":"Barbareschi M, Maisonneuve P, Aldovini D, et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer\u20082003; 983: 474\u201383.","DOI":"10.1002\/cncr.11515"},{"key":"2022061620112388000_B3","doi-asserted-by":"crossref","unstructured":"Stanley MJ, Stanley MW, Sanderson RD, Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol\u20081999; 112: 377\u201383.","DOI":"10.1093\/ajcp\/112.3.377"},{"key":"2022061620112388000_B4","doi-asserted-by":"crossref","unstructured":"Maeda T, Alexander CM, Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res\u20082004; 64: 612\u201321.","DOI":"10.1158\/0008-5472.CAN-03-2439"},{"key":"2022061620112388000_B5","doi-asserted-by":"crossref","unstructured":"Mundhenke C, Meyer K, Drew S, Friedl A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 receptor binding in breast carcinomas. Am J Pathol\u20082002; 160: 185\u201394.","DOI":"10.1016\/S0002-9440(10)64362-3"},{"key":"2022061620112388000_B6","doi-asserted-by":"crossref","unstructured":"Liu D, Shriver Z, Venkataraman G, El Shabrawi Y, Sasisekharan R. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci U S A\u20082002; 99: 568\u201373.","DOI":"10.1073\/pnas.012578299"},{"key":"2022061620112388000_B7","doi-asserted-by":"crossref","unstructured":"Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med\u20081999; 5: 803\u20139.","DOI":"10.1038\/10525"},{"key":"2022061620112388000_B8","doi-asserted-by":"crossref","unstructured":"Vlodavsky I, Friedmann Y, Elkin M, et al. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat Med\u20081999; 5: 793\u2013802.","DOI":"10.1038\/10518"},{"key":"2022061620112388000_B9","doi-asserted-by":"crossref","unstructured":"Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest\u20082001; 108: 341\u20137.","DOI":"10.1172\/JCI13662"},{"key":"2022061620112388000_B10","doi-asserted-by":"crossref","unstructured":"Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem\u20081984; 259: 2283\u201390.","DOI":"10.1016\/S0021-9258(17)43350-3"},{"key":"2022061620112388000_B11","doi-asserted-by":"crossref","unstructured":"Nakajima M, Irimura T, Di Ferrante D, Di Ferrante N, Nicolson GL. Heparan sulfate degradation: relation to tumor invasive and metastatic properties of mouse B16 melanoma sublines. Science\u20081983; 220: 611\u20133.","DOI":"10.1126\/science.6220468"},{"key":"2022061620112388000_B12","unstructured":"Uno F, Fujiwara T, Takata Y, et al. Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res\u20082001; 61: 7855\u201360."},{"key":"2022061620112388000_B13","doi-asserted-by":"crossref","unstructured":"Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta\u20082001; 1471: M99\u2013108.","DOI":"10.1016\/S0304-419X(01)00017-8"},{"key":"2022061620112388000_B14","unstructured":"Parish CR, Freeman C, Brown KJ, Francis DJ, Cowden WB. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity. Cancer Res\u20081999; 59: 3433\u201341."},{"key":"2022061620112388000_B15","unstructured":"Vlodavsky I, Elkin M, Pappo O, et al. Mammalian heparanase as mediator of tumor metastasis and angiogenesis. Isr Med Assoc J\u20082000; 2: 37\u201345."},{"key":"2022061620112388000_B16","unstructured":"Koliopanos A, Friess H, Kleeff J, et al. Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res\u20082001; 61: 4655\u20139."},{"key":"2022061620112388000_B17","unstructured":"Marchetti D, Li J, Shen R. Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res\u20082000; 60: 4767\u201370."},{"key":"2022061620112388000_B18","doi-asserted-by":"crossref","unstructured":"Miao HQ, Elkin M, Aingorn E, Ishai-Michaeli R, Stein CA, Vlodavsky I. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer\u20081999; 83: 424\u201331.","DOI":"10.1002\/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.0.CO;2-L"},{"key":"2022061620112388000_B19","doi-asserted-by":"crossref","unstructured":"Maxhimer JB, Quiros RM, Stewart R, et al. Heparanase-1 expression is associated with the metastatic potential of breast cancer. Surgery\u20082002; 132: 326\u201333.","DOI":"10.1067\/msy.2002.125719"},{"key":"2022061620112388000_B20","doi-asserted-by":"crossref","unstructured":"Watanabe M, Aoki Y, Kase H, Tanaka K. Heparanase expression and angiogenesis in endometrial cancer. Gynecol Obstet Invest\u20082003; 56: 77\u201382.","DOI":"10.1159\/000072821"},{"key":"2022061620112388000_B21","doi-asserted-by":"crossref","unstructured":"Shinyo Y, Kodama J, Hongo A, Yoshinouchi M, Hiramatsu Y. Heparanase expression is an independent prognostic factor in patients with invasive cervical cancer. Ann Oncol\u20082003; 14: 1505\u201310.","DOI":"10.1093\/annonc\/mdg407"},{"key":"2022061620112388000_B22","doi-asserted-by":"crossref","unstructured":"Gohji K, Hirano H, Okamoto M, et al. Expression of three extracellular matrix degradative enzymes in bladder cancer. Int J Cancer\u20082001; 95: 295\u2013301.","DOI":"10.1002\/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A"},{"key":"2022061620112388000_B23","doi-asserted-by":"crossref","unstructured":"Yang Y, Macleod V, Bendre MS, et al. Heparanase expression promotes spontaneous metastasis of myeloma tumor cells to bone. Blood\u20082005; 105: 1303\u20139.","DOI":"10.1182\/blood-2004-06-2141"},{"key":"2022061620112388000_B24","doi-asserted-by":"crossref","unstructured":"Bendre MS, Montague DC, Peery T, Akel NS, Gaddy D, Suva LJ. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for increased osteolysis of metastatic bone disease. Bone\u20082003; 33: 28\u201337.","DOI":"10.1016\/S8756-3282(03)00086-3"},{"key":"2022061620112388000_B25","unstructured":"Bendre MS, Gaddy-Kurten D, Mon-Foote T, et al. Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res\u20082002; 62: 5571\u20139."},{"key":"2022061620112388000_B26","unstructured":"Kelly T, Miao HQ, Yang Y, et al. High heparanase activity in multiple myeloma is associated with elevated microvessel density. Cancer Res\u20082003; 63: 8749\u201356."},{"key":"2022061620112388000_B27","doi-asserted-by":"crossref","unstructured":"Miao HQ, Navarro E, Patel S, et al. Cloning, expression, and purification of mouse heparanase. Protein Expr Purif\u20082002; 26: 425\u201331.","DOI":"10.1016\/S1046-5928(02)00558-2"},{"key":"2022061620112388000_B28","doi-asserted-by":"crossref","unstructured":"Kussie PH, Hulmes JD, Ludwig DL, et al. Cloning and functional expression of a human heparanase gene. Biochem Biophys Res Commun\u20081999; 261: 183\u20137.","DOI":"10.1006\/bbrc.1999.0962"},{"key":"2022061620112388000_B29","doi-asserted-by":"crossref","unstructured":"Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res\u20082004; 64: 2712\u20136.","DOI":"10.1158\/0008-5472.CAN-03-3184"},{"key":"2022061620112388000_B30","unstructured":"Pumphrey CY, Theus AM, Li S, Parrish RS, Sanderson RD. Neoglycans, carbodiimide-modified glycosaminoglycans: a new class of anticancer agents that inhibit cancer cell proliferation and induce apoptosis. Cancer Res\u20082002; 62: 3722\u20138."},{"key":"2022061620112388000_B31","doi-asserted-by":"crossref","unstructured":"Pieters R, Huismans DR, Leyva A, Veerman AJ. Adaptation of the rapid automated tetrazolium dye based (MTT) assay for chemosensitivity testing in childhood leukemia. Cancer Lett\u20081988; 41: 323\u201332.","DOI":"10.1016\/0304-3835(88)90294-7"},{"key":"2022061620112388000_B32","doi-asserted-by":"crossref","unstructured":"Suva LJ, Seedor JG, Endo N, et al. Pattern of gene expression following rat tibial marrow ablation. J Bone Miner Res\u20081993; 8: 379\u201388.","DOI":"10.1002\/jbmr.5650080315"},{"key":"2022061620112388000_B33","doi-asserted-by":"crossref","unstructured":"Christgau S, Rosenquist C, Alexandersen P, et al. Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem\u20081998; 44: 2290\u2013300.","DOI":"10.1093\/clinchem\/44.11.2290"},{"key":"2022061620112388000_B34","unstructured":"Halleen JM. Tartrate-resistant acid phosphatase 5B is a specific and sensitive marker of bone resorption. Anticancer Res\u20082003; 23: 1027\u20139."},{"key":"2022061620112388000_B35","doi-asserted-by":"crossref","unstructured":"Frevert CW, Kinsella MG, Vathanaprida C, et al. Binding of interleukin-8 to heparan sulfate and chondroitin sulfate in lung tissue. Am J Respir Cell Mol Biol\u20082003; 28: 464\u201372.","DOI":"10.1165\/rcmb.2002-0084OC"},{"key":"2022061620112388000_B36","doi-asserted-by":"crossref","unstructured":"Halden Y, Rek A, Atzenhofer W, Szilak L, Wabnig A, Kungl AJ. Interleukin-8 binds to syndecan-2 on human endothelial cells. Biochem J\u20082004; 377: 533\u20138.","DOI":"10.1042\/bj20030729"},{"key":"2022061620112388000_B37","doi-asserted-by":"crossref","unstructured":"Marshall LJ, Ramdin LS, Brooks T, PC DP, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8\/heparan sulfate\/syndecan-1 complexes. J Immunol\u20082003; 171: 2057\u201365.","DOI":"10.4049\/jimmunol.171.4.2057"},{"key":"2022061620112388000_B38","doi-asserted-by":"crossref","unstructured":"Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood\u20082000; 96: 2528\u201336.","DOI":"10.1182\/blood.V96.7.2528.h8002528_2528_2536"},{"key":"2022061620112388000_B39","doi-asserted-by":"crossref","unstructured":"Seidel C, Borset M, Hjertner O, et al. High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood\u20082000; 96: 3139\u201346.","DOI":"10.1182\/blood.V96.9.3139.h8003139_3139_3146"},{"key":"2022061620112388000_B40","doi-asserted-by":"crossref","unstructured":"Murphy MS, John PR, Mayer AD, Buckels JA, Kelly DA. Heparin therapy and bone fractures. Lancet\u20081992; 340: 1098.","DOI":"10.1016\/0140-6736(92)93118-7"},{"key":"2022061620112388000_B41","doi-asserted-by":"crossref","unstructured":"Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol\u20081993; 168: 1265\u201370.","DOI":"10.1016\/0002-9378(93)90378-V"},{"key":"2022061620112388000_B42","doi-asserted-by":"crossref","unstructured":"Muir JM, Hirsh J, Weitz JI, Andrew M, Young E, Shaughnessy SG. A histomorphometric comparison of the effects of heparin and low-molecular-weight heparin on cancellous bone in rats. Blood\u20081997; 89: 3236\u201342.","DOI":"10.1182\/blood.V89.9.3236"},{"key":"2022061620112388000_B43","doi-asserted-by":"crossref","unstructured":"Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood\u20081996; 88: 1314\u201320.","DOI":"10.1182\/blood.V88.4.1314.bloodjournal8841314"},{"key":"2022061620112388000_B44","doi-asserted-by":"crossref","unstructured":"Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood\u20082002; 100: 2530\u20136.","DOI":"10.1182\/blood.V100.7.2530"},{"key":"2022061620112388000_B45","doi-asserted-by":"crossref","unstructured":"Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer\u20082002; 2: 584\u201393.","DOI":"10.1038\/nrc867"},{"key":"2022061620112388000_B46","doi-asserted-by":"crossref","unstructured":"Boyce BF, Yoneda T, Guise TA. Factors regulating the growth of metastatic cancer in bone. Endocr Relat Cancer\u20081999; 6: 333\u201347.","DOI":"10.1677\/erc.0.0060333"},{"key":"2022061620112388000_B47","doi-asserted-by":"crossref","unstructured":"Francini G, Petrioli R, Maioli E, et al. Hypercalcemia in breast cancer. Clin Exp Metastasis\u20081993; 11: 359\u201367.","DOI":"10.1007\/BF00132979"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/13\/5778\/2531899\/5778-5784.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/13\/5778\/2531899\/5778-5784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T20:40:36Z","timestamp":1655412036000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/13\/5778\/518036\/Expression-of-Heparanase-by-Primary-Breast-Tumors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":47,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2005,7,1]]},"published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-0749","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}